Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8.
View in:
PubMed
subject areas
Biomarkers
Clinical Trials, Phase II as Topic
Disease Progression
Humans
Immunologic Factors
Immunotherapy
Multiple Myeloma
Smoldering Multiple Myeloma
authors with profiles
Andrzej Jakubowiak